On January 7, 2022, Jiangsu Asieris Pharmaceuticals Co., Ltd. (“Asieris Pharmaceuticals”, SHSE: 688176) landed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange. It is also the first innovative pharmaceutical company listed on the STAR Market this year.
Asieris Pharmaceuticals is a global innovative pharmaceutical company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. According to the announcement, the number of shares issued by Asieris Pharmaceuticals in this initial public offering (IPO) and listed on the STAR Market is 110 million shares, accounting for 19.30% of the company’s total share capital after the IPO. The issue price is CNY 22.98 per share, and the total amount of funds raised is CNY 2.528 billion.
Asieris Pharmaceuticals is enhancing its product pipeline for genitourinary diseases via 12 ongoing research programs involving 9 major innovative products. Two core products of them, Vesique® (APL-1202) and Cevira® (APL-1702), are targeted at addressing the global unmet needs for the treatment of bladder cancer and cervical precancerous lesions, respectively, and the three corresponding programs are currently in Phase III/pivotal clinical development.
About Asieris
Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
